Clinical Trials List
Protocol NumberCC-220-NHL-001
Completed
2021-12-15 - 2025-08-31
Phase I/II
Terminated3
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ming-Chung Kao Division of Hematology & Oncology
- Tung-Liang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Wei-Ching Lin Division of Radiology
- Ching-Chan Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
232 participants
